Näytä suppeat kuvailutiedot

Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study

Oksanen Pia; Koskinen Inka; Eronen Heli; Huhtala Heini; Jussila Airi; Kolehmainen Sara; Sipponen Taina; Koffert Jukka; Ilus Tuire

dc.contributor.authorOksanen Pia
dc.contributor.authorKoskinen Inka
dc.contributor.authorEronen Heli
dc.contributor.authorHuhtala Heini
dc.contributor.authorJussila Airi
dc.contributor.authorKolehmainen Sara
dc.contributor.authorSipponen Taina
dc.contributor.authorKoffert Jukka
dc.contributor.authorIlus Tuire
dc.date.accessioned2022-10-27T12:27:49Z
dc.date.available2022-10-27T12:27:49Z
dc.identifier.urihttps://www.utupub.fi/handle/10024/158770
dc.description.abstract<p><strong>Background and aims: </strong>Therapy with two concomitant biologicals targeting different inflammatory pathways has emerged as a new therapy option for treatment refractory inflammatory bowel disease (IBD). Data on the efficacy and safety of dual biological therapy (DBT) are scarce and are investigated in this study.</p><p><strong>Materials and methods: </strong>Data on all patients treated with a combination of two biologicals in four Finnish tertiary centres were collected and analysed. Remission was assessed by a physician on the basis of biomarkers, endoscopic evaluation and alleviation of symptoms.</p><p><strong>Results: </strong>A total of 16 patients with 22 trials of DBT were included. Fifteen patients had Crohn's disease. The most common combination of DBT was adalimumab (ADA) and ustekinumab (USTE; 36%) with median follow-up of nine months (range 2-31). Altogether seven (32%) patients were in remission at the end of follow-up and in two trials response to DBT was assessed to be partial with the relief of patient symptoms. In a total of four trials DBT reduced the need for corticosteroids. The majority of patients achieving a response to DBT were treated with the combination of ADA and USTE (56%). At the end of follow-up all nine (41%) patients responding to DBT continued treatment. Infection complications occurred in three patients (19%).</p><p><strong>Conclusion: </strong>DBT is a promising alternative treatment for refractory IBD, and half of our patients benefitted from it. More data on the efficacy and safety of DBT are needed especially in long-term follow up.</p>
dc.language.isoen
dc.publisherTaylor and Francis [Commercial Publisher]
dc.titleCombining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study
dc.identifier.urnURN:NBN:fi-fe2022081153947
dc.contributor.organizationfi=kliinisen laitoksen yhteiset|en=Department of Clinical Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, vsshp|
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organization-code2607300
dc.contributor.organization-code2607318
dc.converis.publication-id174791578
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/174791578
dc.identifier.eissn1502-7708
dc.identifier.jour-issn0036-5521
dc.okm.affiliatedauthorKoffert, Jukka
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeJournal article
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1080/00365521.2022.2045350
dc.relation.ispartofjournalScandinavian Journal of Gastroenterology
dc.year.issued2022


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot